Edition:
United States

Cadila Healthcare Ltd (CADI.NS)

CADI.NS on National Stock Exchange of India

473.40INR
6:25am EDT
Change (% chg)

Rs-8.20 (-1.70%)
Prev Close
Rs481.60
Open
Rs478.00
Day's High
Rs478.00
Day's Low
Rs465.00
Volume
953,394
Avg. Vol
1,187,606
52-wk High
Rs560.00
52-wk Low
Rs328.80

Latest Key Developments (Source: Significant Developments)

Cadila Healthcare says Zydus gets U.S. FDA nod for telmisartan, hydrochlorothiazide tablets
Thursday, 17 Aug 2017 12:51am EDT 

Aug 17 (Reuters) - Cadila Healthcare Ltd :Says Zydus receives final approval from USFDA for telmisartan and hydrochlorothiazide tablets.Drug will be manufactured at group's formulations manufacturing facility at Moraiya, Ahmedabad.Says telmisartan and hydrochlorothiazide tablets are used to treat hypertension .  Full Article

Cadila Healthcare gets USFDA approval for Tiadylt ER capsules and nasal spray
Wednesday, 16 Aug 2017 01:42am EDT 

Aug 16 (Reuters) - Cadila Healthcare Ltd :Gets final approval from USFDA for Tiadylt Er capsules and Azelastine Hydrochloride nasal spray.Azelastine hydrochloride nasal spray will be manufactured at formulations manufacturing facility at Moraiya, Ahmedabad.  Full Article

Cadila Healthcare says Zydus gets tentative approval from USFDA for mesalamine suppositories
Friday, 11 Aug 2017 06:41am EDT 

Aug 11 (Reuters) - Cadila Healthcare Ltd ::Says Zydus receives tentative approval from USFDA for mesalamine suppositories for rectal use.  Full Article

India's Cadila Healthcare June-qtr consol profit falls 65 pct
Friday, 11 Aug 2017 02:09am EDT 

Aug 11 (Reuters) - Cadila Healthcare Ltd :June quarter consol net profit 1.38 billion rupees versus profit of 3.98 billion rupees last year.June quarter consol total income 22.50 billion rupees versus 23.48 billion rupees last year.  Full Article

Cadila Healthcare says Zydus gets final nod from U.S. FDA for diltiazem hydrochloride extended-release capsules USP
Wednesday, 9 Aug 2017 01:39am EDT 

Aug 9 (Reuters) - Cadila Healthcare Ltd :Says Zydus receives final approval from USFDA for diltiazem hydrochloride extended-release capsules USP.Drug used for treatment of hypertension, angina and certain heart rhythm disorders.Says drug will be produced in group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad.  Full Article

Cadila Healthcare says Zydus gets tentative nod from U.S. FDA for Abacavir & Lamivudine tablets USP
Tuesday, 8 Aug 2017 02:45am EDT 

Aug 8 (Reuters) - Cadila Healthcare Ltd :Says Zydus receives tentative approval from USFDA for Abacavir and Lamivudine tablets USP.Says drug will be produced at group's formulations manufacturing facility at Pharma SEZ in Ahmedabad.  Full Article

Cadila Healthcare says Zydus gets final approval from U.S. FDA for Temozolomide Capsules & Nadolol Tablets USP.
Tuesday, 1 Aug 2017 02:15am EDT 

Aug 1 (Reuters) - Cadila Healthcare Ltd ::Says Zydus receives final approval from USFDA for Temozolomide capsules and Nadolol Tablets USP..Says both the drugs will be manufactured at group's formulations unit at Pharma SEZ, Ahmedabad.  Full Article

Cadila Healthcare says Zydus receives final approval from U.S. FDA for Mesalamine Delayed -Release tablets
Tuesday, 25 Jul 2017 02:38am EDT 

July 25 (Reuters) - Cadila Healthcare Ltd :Says 'Zydus receives final approval from USFDA for Mesalamine Delayed -Release tablets, 800 mg'..Says drug will be manufactured at the group's formulation manufacturing facility at Moraiya.  Full Article

Cadila Healthcare says Zydus receives final approval from the U.S. FDA for Tranexamic Acid Injection
Wednesday, 19 Jul 2017 05:51am EDT 

July 19 (Reuters) - Cadila Healthcare Ltd ::Says Zydus receives final approval from the USFDA for Tranexamic Acid injection.Says Tranexamic medication will be produced at group's formulation manufacturing facility at Moraiya.Tranexamic acid injections used to prevent bleeding in patients with Haemophilia undergoing tooth extraction.  Full Article

Cadila Healthcare says Zydus launches drug to treat ulcerative colitis in the U.S.
Tuesday, 18 Jul 2017 11:45pm EDT 

July 19 (Reuters) - Cadila Healthcare Ltd :Says Zydus launches mesalamine delayed release tablets in the U.S..Says drug is indicated for treatment of mild to moderate ulcerative colitis.  Full Article

BRIEF-Cadila Healthcare gets USFDA approval for Tiadylt ER capsules and nasal spray

* Gets final approval from USFDA for Tiadylt Er capsules and Azelastine Hydrochloride nasal spray